Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00818675 | A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1) | terminated | Phase 2 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 21, 2015 | clinicaltrials |
| NCT01761747 | Ponatinib for Squamous Cell Lung and Head and Neck Cancers | terminated | Phase 2 / Phase 3 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00452075 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy | terminated | Phase 2 | 24 | Rigshospitalet, DenmarkOTHER | 1 | Dec 11, 2014 | clinicaltrials |
| NCT01664663 | Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy(PLANET) | terminated | Phase 2 | 37 | Ass. Prof. Jan NymanNETWORK | 1 | Dec 9, 2014 | clinicaltrials |
| NCT01038037 | First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer(Lung-TRIO) | terminated | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00549328 | Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 1 | Nov 19, 2014 | clinicaltrials |
| NCT01049776 | GW786034 in Patients With Non Small Cell Lung Cancer 3rd Line | terminated | Phase 2 | 32 | Illinois CancerCare, P.C.OTHER | 1 | Sep 19, 2014 | clinicaltrials |
| NCT02127372 | Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571 | terminated | Phase 1 / Phase 2 | 43 | Duke UniversityOTHER | 0 | Sep 15, 2014 | clinicaltrials |
| NCT00509366 | Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer(TOP0602) | terminated | Phase 2 | 101 | Duke UniversityOTHER | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00545948 | Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer(TOP0703) | terminated | Phase 2 | 31 | Duke UniversityOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT01491633 | Dasatinib in Advanced Squamous Cell Lung Cancer | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2014 | clinicaltrials |
| NCT02157116 | Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 13 | Duke UniversityOTHER | 1 | Jul 4, 2014 | clinicaltrials |
| NCT00145418 | Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00976677 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00084487 | Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00614484 | Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Loma Linda UniversityOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01471197 | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Bristol-Myers SquibbINDUSTRY | 5 | May 12, 2014 | clinicaltrials |
| NCT00203931 | Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer | terminated | Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT01356368 | Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer(Customizing) | terminated | Phase 2 | 3 | National Guard Health AffairsOTHER_GOV | 1 | Jan 22, 2014 | clinicaltrials |
| NCT01640730 | Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer | terminated | Phase 2 | 1 | KangLaiTe USAINDUSTRY | 1 | Jan 16, 2014 | clinicaltrials |
| NCT01871480 | CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer | terminated | Phase 2 | 50 | Kunming Medical UniversityOTHER | 1 | Dec 30, 2013 | clinicaltrials |
| NCT00887315 | The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)(SMART) | terminated | Phase 2 | 11 | University of ChicagoOTHER | 1 | Dec 6, 2013 | clinicaltrials |
| NCT00701870 | Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer | terminated | Phase 2 | 1 | TelikINDUSTRY | 1 | Nov 27, 2013 | clinicaltrials |
| NCT00365183 | Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer | terminated | Phase 2 | 74 | Pharmacyclics LLC.INDUSTRY | 1 | Oct 31, 2013 | clinicaltrials |
| NCT01337154 | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 140 | CytRxINDUSTRY | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00773383 | A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy. | terminated | Phase 2 | 35 | Hoffmann-La RocheINDUSTRY | 4 | Jun 24, 2013 | clinicaltrials |
| NCT00087269 | Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection | terminated | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC | terminated | Phase 1 / Phase 2 | 2 | Armando Santoro, MDOTHER | 1 | May 29, 2013 | clinicaltrials |
| NCT00758134 | Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients | terminated | Phase 2 | 9 | Armando Santoro, MDOTHER | 1 | May 29, 2013 | clinicaltrials |
| NCT00977561 | A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 2 | 9 | PfizerINDUSTRY | 4 | Feb 25, 2013 | clinicaltrials |
| NCT00705549 | Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | terminated | Phase 2 | 88 | Hellenic Oncology Research GroupOTHER | 1 | Feb 13, 2013 | clinicaltrials |
| NCT00776295 | Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00040768 | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00862134 | Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 42 | Proacta, IncorporatedINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT01004510 | Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer(ZAP) | terminated | Phase 2 | 3 | Peter Bushunow MDOTHER | 1 | Dec 4, 2012 | clinicaltrials |
| NCT00694603 | Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy | terminated | Phase 2 | 56 | Lecia V. SequistOTHER | 1 | Sep 6, 2012 | clinicaltrials |
| NCT00093132 | Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy | terminated | Phase 1 / Phase 2 | 20 | AgennixINDUSTRY | 1 | Aug 17, 2012 | clinicaltrials |
| NCT00522938 | Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 2 | Chroma TherapeuticsINDUSTRY | 1 | Jun 28, 2012 | clinicaltrials |
| NCT00291850 | Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC | terminated | Phase 2 | 50 | Central European Cooperative Oncology GroupOTHER | 3 | May 1, 2012 | clinicaltrials |
| NCT00460551 | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer | terminated | Phase 2 | 13 | GenmabINDUSTRY | 5 | Dec 6, 2011 | clinicaltrials |
| NCT00830245 | A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer | terminated | Phase 2 | 20 | Clinical Research Center for Solid Tumor, KoreaOTHER | 1 | Jul 26, 2011 | clinicaltrials |
| NCT00369447 | A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 52 | YM BioSciencesINDUSTRY | 3 | Jul 1, 2011 | clinicaltrials |
| NCT00872482 | A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases | terminated | Phase 2 | 21 | YM BioSciencesINDUSTRY | 5 | Jul 1, 2011 | clinicaltrials |
| NCT00343187 | A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash | terminated | Phase 2 | 2 | AllerganINDUSTRY | 1 | May 30, 2011 | clinicaltrials |
| NCT00232206 | Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer | terminated | Phase 2 | 40 | Providence Health & ServicesOTHER | 1 | May 18, 2011 | clinicaltrials |
| NCT00216216 | Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer | terminated | Phase 2 | 43 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT00117351 | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features | terminated | Phase 2 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00283634 | A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00354562 | A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 75 | AbbottINDUSTRY | 4 | Jan 7, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2015source: clinicaltrials